Drug Trial Radar · NCT04601051
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 5, 2020
Primary completion
Sep 12, 2025
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- Intellia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM)
Conditions
- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- Wild-Type Transthyretin Cardiac Amyloidosis
Interventions
NTLA-2001Biological
A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse EventsTime frame: up to Day 730
- Number of Participants with Clinically Significant Clinical Laboratory Test FindingsTime frame: up to Day 730
- Number of Participants with Clinically Significant Safety MeasurementsTime frame: up to Day 730
- Percent Change from Baseline in Serum TTR (enzyme-linked immunosorbent assay [ELISA])Time frame: up to Day 730
- Percent Change from Baseline in Serum PrealbuminTime frame: up to Day 730
- Mean Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUClast) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNATime frame: up to Day 730
- Mean Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNATime frame: up to Day 730
- Mean Maximum Concentration (Cmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNATime frame: up to Day 730
- Mean Time of the Maximum Concentration (Tmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNATime frame: up to Day 730
- Mean Terminal Half-Life (t½) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNATime frame: up to Day 730
- Mean Apparent Clearance (CL) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNATime frame: up to Day 730
- Mean Volume of Distribution (Vd) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNATime frame: up to Day 730
- Change from Baseline in Anti-Drug Antibody to NTLA-2001 and Anti-Cas9 Protein Antibody to Transgene Product LevelsTime frame: up to Day 730
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Paris, France
Clinical Trial Site
Auckland, New Zealand
Clinical Trial Site
Umeå, Sweden
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.